FARON PHARMACEUTICALS OY
Clinical-stage biopharmaceutical company developing immunotherapies for cancer.
FARN | IL
Overview
Corporate Details
- ISIN(s):
- FI4000153309
- LEI:
- 7437009H31TO1DC0EB42
- Country:
- Finland
- Address:
- Joukahaisenkatu 6, FI-20520 TURKU
- Website:
- https://faron.com/
- Sector:
- Manufacturing
Description
Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-08-29 08:00 |
FDA Orphan Drug Designation for Bexmarilimab
|
English | 17.9 KB | ||
| 2023-08-04 08:00 |
Notice of Half-Year Financial Results
|
English | 16.8 KB | ||
| 2023-08-02 08:00 |
Faron to Participate at Canaccord Conference
|
English | 14.5 KB | ||
| 2023-07-25 08:00 |
Grant of Options
|
English | 46.3 KB | ||
| 2023-07-19 08:01 |
Faron to Hold BEXMAB Study Conference Call
|
English | 15.3 KB | ||
| 2023-07-19 08:00 |
BEXMAB study update
|
English | 22.2 KB | ||
| 2023-06-30 17:52 |
Holding(s) in Company
|
English | 51.5 KB | ||
| 2023-06-29 08:00 |
Announcement of Placing
|
English | 66.8 KB | ||
| 2023-06-12 08:00 |
Exercise of options
|
English | 14.0 KB | ||
| 2023-06-09 09:00 |
New biomarker data from BEXMAB study at EHA2023
|
English | 20.9 KB | ||
| 2023-06-05 08:00 |
Board Member to Assume Transactional Advisor Role
|
English | 16.3 KB | ||
| 2023-04-24 08:00 |
Bexmarilimab Efficacy and Safety in MATINS Trial
|
English | 16.3 KB | ||
| 2023-04-19 08:00 |
Bexmarilimab KOL Event
|
English | 18.0 KB | ||
| 2023-04-18 08:00 |
Poster Presentations at AACR 2023
|
English | 17.8 KB | ||
| 2023-04-17 08:00 |
BEXMAB study update
|
English | 21.7 KB |
Automate Your Workflow. Get a real-time feed of all FARON PHARMACEUTICALS OY filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for FARON PHARMACEUTICALS OY
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for FARON PHARMACEUTICALS OY via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
